United States Patent 9,556,263: Claim Validity, Scope, and US Patent Landscape for Eculizumab Formulation Protection

US Patent 9,556,263 protects a narrow formulation and storage-performance envelope for eculizumab in a specific stabilized aqueous composition, plus method claims for use in atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The core inventive content is the combination of (1) excipient selection and ratios (histidine/serine/sorbitol/mannitol), (2) eculizumab concentration window, and (3) explicit monomer/aggregation/fragmentation and functional retention targets after cold storage. The most attackable elements are (a) novelty of the excipient system at the stated levels and (b) whether the breadth of the concentration and pH ranges reads on previously disclosed “stable eculizumab” formulations, leaving only the SEC-HPLC and functional-retention thresholds as the distinguishing hook.

What exactly does US 9,556,263 claim?

The claims are method claims tied to administering a stable aqueous solution containing eculizumab, with additional dependent claims that lock formulation quality attributes and storage performance. The principal limitations cluster into three tiers: composition, process/performance, and therapeutic indication.

1) Composition limitations (independent claims 1-4)

All independent claims require the same excipient system and same concentration window for eculizumab, plus fixed ranges for the stabilizers:

Element	Claims 1,3 (comprising)	Claims 2,4 (consisting of)
Target condition	aHUS (claims 1-2) / PNH (claims 3-4)	same
Active	eculizumab	eculizumab
Eculizumab concentration	~100 mg/mL to ~200 mg/mL	same
Histidine	~20 mM	~20 mM
Serine	~50 mM	~50 mM
Sorbitol	~3% (w/v)	~3% (w/v)
Mannitol	~1.5% (w/v)	~1.5% (w/v)
Base requirement	“stable aqueous solution”	“stable aqueous solution consisting of” stated components

Scope impact of “comprising” vs “consisting of.”
Claims 1 and 3 allow additional components (“comprising”) as long as the listed ingredients are present and the solution is “stable.” Claims 2 and 4 narrow to solutions that “consist[] of” the listed components (still within the stated concentration/amount ranges). In infringement practice, “consisting of” can block design-arounds that include extra buffers/surfactants/chelators, unless the added materials are characterized as impurities or trace residuals.

2) pH constraint (claims 5-6)

Claim 5: pH between 6.5 and 7.5
Claim 6: pH is 7.0

This is a medium-strength dependent constraint: many biologic formulations fall in this bracket, so pH alone is unlikely to be the differentiator unless prior art formulations are outside it or use different buffering systems.

3) Quantitative stability criteria (claims 7-13)

These depend on eculizumab quality during refrigerated storage (2°C to 8°C) and are defined using SEC-HPLC monomer, aggregation, fragmentation, and functional readouts.

Claim	Additional limitation
7	anti-C5 antibody at 100 mg/mL
8	≥97% monomeric after storage 2°C-8°C for ≥6 months (SEC-HPLC)
9	≥97% monomeric after storage 2°C-8°C for ≥1 year (SEC-HPLC)
10	<2% aggregated (SEC-HPLC)
11	<1% fragmented (SEC-HPLC)
12	retains ≥90% C5-binding activity after ≥6 months (vs reference pre-storage)
13	retains ≥95% hemolysis inhibition after ≥6 months (vs reference pre-storage)

Critical note on enforceability leverage.
If the “stable formulation” term is attacked as indefinite or overly broad, claims 8-13 supply objective numeric endpoints. That structure tends to shift validity fights toward whether those targets were achieved (and were enabled/disclosed) by earlier formulations using the same excipient system and ranges.

4) Administration route (claim 14)

Intravenous infusion.

Route limits can matter if prior art uses subcutaneous delivery, injection, or alternative administration forms. For eculizumab, US-commercial practice has been IV infusion; route may be less likely to provide novelty.

Where does the landscape risk sit: novelty, non-obviousness, and claim construction?

The strongest validity pressure typically comes from earlier patents and filings on:

eculizumab formulation stabilization (excipient selection and ratios), and
refrigerated stability targets (monomer/aggregation/fragmentation; binding/function retention), and
the same therapeutic indications (aHUS/PNH) with known dosing/administration.

A formulation patent’s vulnerability is that it often inherits a known therapeutic use (eg, eculizumab for PNH). That makes novelty harder to find in the “method of treating” language unless the formulation itself is meaningfully distinct.

A) Novelty: are the excipient combinations already known?

For US 9,556,263, the likely novelty-differentiator is not “stabilizers in general,” but the specific combination and ratios:

Histidine at ~20 mM
Serine at ~50 mM
Sorbitol at ~3% (w/v)
Mannitol at ~1.5% (w/v)
Eculizumab at ~100-200 mg/mL

If earlier disclosures describe essentially the same formulation (or a directly overlapping one, including stability outcomes), then independent claims 1-4 face a direct novelty hit. The “comprising” language makes it easier to read on prior art solutions that may include minor additional components (for novelty/infringement, the added component issue depends on how prior art defines its formulations).

B) Non-obviousness: stability outcomes and the “obviousness trap”

Even if excipient ratios are not identically disclosed, challengers commonly argue obviousness by combining:

generic formulation guidance for monoclonal antibodies (buffer + amino acid + sugar alcohols),
known behavior of histidine and serine as stabilizers,
known use of sorbitol/mannitol for tonicity and freeze/thaw stabilization,
and standard SEC-HPLC readouts as routine stability characterization.

The patent’s dependent claims 8-13 attempt to avoid that trap by tying the excipient formulation to quantified performance benchmarks. The central question in non-obviousness becomes whether it would have been routine to obtain ≥97% monomer, <2% aggregates, <1% fragments, and functional retention ≥90% binding and ≥95% hemolysis inhibition at 2°C-8°C for the stated durations, using the specified excipient system.

C) Claim construction: “stable” vs numeric endpoints

Independent claims rely on “stable” while the dependent claims define stability via SEC-HPLC and functional assays. If “stable” is interpreted broadly, it can widen claim scope to formulations that meet the numeric metrics only when measured under particular conditions. Conversely, if “stable” is constrained by the dependent numeric endpoints as the intrinsic meaning, it narrows the practical claim reach.

D) Enabling disclosure and burden of proof dynamics

To invalidate, challengers typically aim to show earlier formulations were both:

within the claimed composition ranges; and
actually stable by recognized testing methods.

Because claims 8-13 are numeric and methodologically anchored to SEC-HPLC and functional assays, the patent’s enforceability often tracks how closely challengers can match those endpoints.

Which claim elements are most likely to be targeted in litigation or PTAB challenges?

Below is a practical attack map ordered by typical litigation focus (from highest risk to lower risk) for formulation-and-method patents like this.

1) Independent composition claims (1-4)

Primary attack vector: prior art eculizumab formulations with overlapping excipient systems and concentration windows.

Claims 1 and 3 (“comprising”) are more readable onto partially overlapping prior art.
Claims 2 and 4 (“consisting of”) are narrower but still vulnerable if prior art formulations are essentially identical in component set.

2) Dependent stability-performance claims (8-13)

Primary attack vector: earlier patents or development reports showing the same or superior stability outcomes using the same (or sufficiently close) formulation components.

These claims are often a “last mile” differentiator. If earlier art does not measure monomer/aggregation/fragmentation or does not report functional retention vs pre-storage, those claims can remain resilient. But if earlier art reports similar data, these become invalidation magnets.

3) pH and concentration narrowing (5-6, 7, 9)

These constraints can be powerful if prior art uses different pH/buffering agents or different concentrations. If prior art spans a similar pH window and concentration range, these limits reduce less than expected.

4) Indications (aHUS and PNH)

Eculizumab’s use in PNH is well established, and aHUS is also established in clinical and regulatory contexts. In practice, therapeutic indication limitations typically do not save a formulation claim if the formulation itself is not novel and non-obvious. The indications can matter mainly for infringement on method claims if use in the specified indication is disputed, but challenge strategies usually focus on formulation validity.

How “design-around” likely works against US 9,556,263

The claims impose constraints that can be avoided through either formulation component changes or by moving outside key thresholds.

Likely design-around levers

Change one excipient outside the claimed amount window
The claimed amounts are specific enough to enable avoidance by changing histidine, serine, sorbitol, or mannitol concentrations. A small shift can move a product outside the “about” ranges if “about” is construed narrowly in view of the specification.
Add additional components to reach “consisting of” failure (for claims 2 and 4)
If a competitor uses “consisting of” claims as the infringement target, adding a trace excipient such as surfactant or chelator (if supported for stability) can break literal infringement on “consisting of” formulations.
Target concentration outside the 100-200 mg/mL window
Altering protein concentration can bypass independent claims 1-4 and dependent claim 7, if the product is outside “about” boundaries.
Use different storage-stability strategy to avoid meeting the numeric thresholds
Even if the formulation is similar, failing to achieve ≥97% monomer or <2% aggregates, or missing the ≥90% binding and ≥95% hemolysis inhibition retention targets, can avoid claims 8-13 if those endpoints are treated as required limitations.

Likely constraints on successful design-arounds

Because the claims are anchored to objective performance metrics, challengers can force comparability. If a competitor changes components but still achieves identical stability metrics, the competitor risks infringement depending on how “stable” and the stability endpoints are interpreted.

What does this mean for the US patent landscape strategy?

US 9,556,263 is best viewed as a formulation and stability IP moat around refrigerated storage performance for eculizumab at high concentration with a defined excipient system. For business and investment decisions, the key is whether the surrounding patent family and subsequent continuation/divisional activity create a layered coverage map that blocks close variants.

Coverage pattern implied by the claims

Independent coverage: formulation composition + concentration + therapeutic method (aHUS or PNH).
Dependent “quality gating”: numeric monomer/aggregation/fragmentation and functional retention.
Additional gating: pH and specific antibody concentration (100 mg/mL).
Route: IV infusion.

This pattern is typical of formulation portfolios that try to capture both literal composition and performance-based equivalents.

Landscape implications to test (strategic lens)

Are there earlier “same excipient system” filings? If yes, independent claims are at risk.
Are there earlier filings that disclose matching SEC-HPLC monomer and functional retention? If yes, the dependent claims 8-13 are at risk.
Does later art converge on the same excipient ratios and stability outcomes? If yes, the moat narrows because the field may have standardized around the claimed formulation envelope.
Are there gaps in the record for specific time points (6 months vs 1 year) and thresholds (97% monomer, <2% aggregates, <1% fragments)? If earlier art stops short of those endpoints, the dependent claims hold value.

Key Takeaways

US 9,556,263 protects a specific eculizumab stabilized aqueous formulation defined by excipient identity and amounts (histidine ~20 mM, serine ~50 mM, sorbitol ~3% w/v, mannitol ~1.5% w/v) and an eculizumab concentration window (~100-200 mg/mL), with stability quantified by SEC-HPLC and functional retention after 2°C-8°C storage.
The strongest enforceability leverage is in dependent claims 8-13 because they require objective stability and activity endpoints (≥97% monomer; <2% aggregates; <1% fragments; ≥90% C5 binding activity; ≥95% hemolysis inhibition after ≥6 months).
The most plausible invalidity route for challengers is prior disclosure of essentially the same excipient system and concentration range for eculizumab with matching refrigerated stability outcomes; indications and IV route are comparatively lower-value differentiators.
“Comprising” vs “consisting of” matters: the latter narrows infringement risk against formulations that include additional stabilizing components.

FAQs

1) What is the core novelty theme of US 9,556,263?

The formulation composition plus concentration window and the quantified stability and functional retention metrics after refrigerated storage.

2) Which claims provide the strongest numeric constraints?

Claims 8-13 because they recite explicit SEC-HPLC monomer/aggregation/fragmentation thresholds and functional retention targets for C5-binding and hemolysis inhibition.

3) How does “comprising” change claim scope?

It allows additional ingredients beyond the listed excipients, increasing the chance of reading on formulations that include extra components.

4) What is the practical design-around approach?

Alter at least one of: excipient identity/amounts, eculizumab concentration window, pH, or storage stability outcomes so that the numeric thresholds are not met.

5) Do the disease indications drive patent strength?

They typically add method-claim context, but for formulation patents, the formulation limitations drive novelty and infringement more than the specific indications (aHUS and PNH).

References

[1] US Patent 9,556,263. “Method for treating a patient having atypical hemolytic uremic syndrome (aHUS) or paroxysmal nocturnal hemoglobinuria (PNH) with a stable aqueous eculizumab solution.” (Claims provided in the prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	March 16, 2007	⤷ Start Trial	2036-06-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 9,556,263

Summary for Patent: 9,556,263